Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 875

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Gastric cancer

Open access
Hartgrink, Henk H, Jansen, Edwin PM, van Grieken, Nicole CT, van de Velde, Cornelis JH·2009·The Lancet
DOI 10.1016/s0140-6736(09)60617-6
Open this paper in CoChat — free account

Abstract

Gastric cancer is the second most frequent cause of cancer death worldwide, although much geographical variation in incidence exists. Prevention and personalised treatment are regarded as the best options to reduce gastric cancer mortality rates. Prevention strategies should be based on specific risk profiles, including Helicobacter pylori genotype, host gene polymorphisms, presence of precursor lesions, and environmental factors. Although adequate surgery remains the cornerstone of gastric cancer treatment, this single modality treatment seems to have reached its maximum achievable effect for local control and survival. Minimally invasive techniques can be used for treatment of early gastric cancers. Achievement of locoregional control for advanced disease remains very difficult. Extended resections that are standard practice in some Asian countries have not been shown to be as effective in other developed countries. We present an update of the incidence, causes, pathology, and treatment of gastric cancer, consisting of surgery, new strategies with neoadjuvant and adjuvant chemotherapy or radiotherapy, or both, novel treatment strategies using gene signatures, and the effect of caseload on patient outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(09)60617-6

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 172

  1. Kamangar, 2006, Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world, J Clin Oncol, 24, 2137, 10.1200/JCO.2005.05.2308 · DOI · Paper page
  2. Yamaoka, 2008, Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains, Intern Med, 47, 1077, 10.2169/internalmedicine.47.0975 · DOI · Paper page
  3. Tsugane, 2007, Diet and the risk of gastric cancer: review of epidemiological evidence, Gastric Cancer, 10, 75, 10.1007/s10120-007-0420-0 · DOI · Paper page
  4. Bae, 2008, Citrus fruit intake and stomach cancer risk: a quantitative systematic review, Gastric Cancer, 11, 23, 10.1007/s10120-007-0447-2 · DOI
  5. Hanley, 1995, Cancer mortality among Chinese migrants: a review, Int J Epidemiol, 24, 255, 10.1093/ije/24.2.255 · doi:10.1093/ije/24.2.255
  6. 2001, Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts, Gut, 49, 347, 10.1136/gut.49.3.347 · DOI · Paper page
  7. Ladeiras-Lopes, 2008, Smoking and gastric cancer: systematic review and meta-analysis of cohort studies, Cancer Causes Control, 19, 689, 10.1007/s10552-008-9132-y · DOI · Paper page
  8. Crew, 2006, Epidemiology of gastric cancer, World J Gastroenterol, 12, 354, 10.3748/wjg.v12.i3.354 · DOI · Paper page
  9. Parkin, 2001, Global cancer statistics in the year 2000, Lancet Oncol, 29, 533, 10.1016/S1470-2045(01)00486-7 · DOI · Paper page
  10. Gunderson, 1982, Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy, Int J Radiat Oncol Biol Phys, 8, 1, 10.1016/0360-3016(82)90377-7 · DOI · Paper page
  11. Guilford, 1999, E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer, Hum Mutat, 14, 249, 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9 · DOI · Paper page
  12. Barber, 2008, Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer, J Pathol, 216, 295, 10.1002/path.2426 · DOI
  13. Brooks-Wilson, 2004, Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria, J Med Genet, 41, 508, 10.1136/jmg.2004.018275 · DOI · Paper page
  14. Gylling, 2007, Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study, Gut, 56, 926, 10.1136/gut.2006.114876 · DOI
  15. Shinmura, 2005, A novel STK11 germline mutation in two siblings with Peutz-Jeghers syndrome complicated by primary gastric cancer, Clin Genet, 67, 81, 10.1111/j.1399-0004.2005.00380.x · DOI
  16. Correa, 1992, Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society Award lecture on cancer epidemiology and prevention, Cancer Res, 52, 6735
  17. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ; 302: 1302–05. · DOI · Paper page
  18. Nomura, 1991, Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii, N Engl J Med, 325, 1132, 10.1056/NEJM199110173251604 · DOI · Paper page
  19. Parsonnet, 1991, Helicobacter pylori infection and the risk of gastric carcinoma, N Engl J Med, 325, 1127, 10.1056/NEJM199110173251603 · DOI · Paper page
  20. Uemura, 2001, Helicobacter pylori infection and the development of gastric cancer, N Engl J Med, 345, 784, 10.1056/NEJMoa001999 · DOI · Paper page
  21. Canedo, 2008, The interferon gamma receptor 1 (IFNGR1) -56C/T gene polymorphism is associated with increased risk of early gastric carcinoma, Gut, 57, 1504, 10.1136/gut.2007.143578 · doi:10.1136/gut.2007.143578
  22. El-Omar, 2000, Interleukin-1 polymorphisms associated with increased risk of gastric cancer, Nature, 404, 398, 10.1038/35006081 · DOI · Paper page
  23. Hold, 2007, A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors, Gastroenterology, 132, 905, 10.1053/j.gastro.2006.12.026 · DOI · Paper page
  24. Fox, 2000, Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy, Nat Med, 6, 536, 10.1038/75015 · DOI · Paper page
  25. Franco, 2008, Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors, Cancer Res, 68, 379, 10.1158/0008-5472.CAN-07-0824 · DOI · Paper page
  26. Palli, 2007, CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study, Int J Cancer, 120, 859, 10.1002/ijc.22435 · DOI
  27. Liu, 2008, Nutrition and gastric cancer risk: an update, Nutr Rev, 66, 237, 10.1111/j.1753-4887.2008.00029.x · DOI
  28. Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 · DOI · Paper page
  29. Baylin, 1998, Alterations in DNA methylation: a fundamental aspect of neoplasia, Adv Cancer Res, 72, 141, 10.1016/S0065-230X(08)60702-2 · DOI · Paper page
  30. Ottini, 2006, Patterns of genomic instability in gastric cancer: clinical implications and perspectives, Ann Oncol, 17, 97, 10.1093/annonc/mdl960 · doi:10.1093/annonc/mdl960
  31. Suzuki, 2006, Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage, Cancer Cell, 9, 199, 10.1016/j.ccr.2006.02.016 · DOI · Paper page
  32. Bacani, 2005, Tumor microsatellite instability in early onset gastric cancer, J Mol Diagn, 7, 465, 10.1016/S1525-1578(10)60577-6 · DOI
  33. Ottini, 2004, MRE11 expression is impaired in gastric cancer with microsatellite instability, Carcinogenesis, 25, 2337, 10.1093/carcin/bgh257 · DOI
  34. Fleisher, 1999, Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability, Cancer Res, 59, 1090
  35. Beghelli, 2006, Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers, Surgery, 139, 347, 10.1016/j.surg.2005.08.021 · DOI
  36. Wu, 2000, Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes, Genes Chromosomes Cancer, 27, 403, 10.1002/(SICI)1098-2264(200004)27:4<403::AID-GCC10>3.0.CO;2-1 · doi:10.1002/(sici)1098-2264(200004)27:4<403::aid-gcc10>3.0.co;2-1
  37. Meyers, 2001, Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses, Cancer Res, 61, 5193
  38. Elsaleh, 2001, Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma, Clin Colorectal Cancer, 1, 104, 10.3816/CCC.2001.n.010 · DOI
  39. Grundei, 2000, Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma, Clin Cancer Res, 6, 4782
  40. Aguilera, 2008, Genome instability: a mechanistic view of its causes and consequences, Nat Rev Genet, 9, 204, 10.1038/nrg2268 · DOI · Paper page
  41. Buffart, 2007, Gastric cancers in young and elderly patients show different genomic profiles, J Pathol, 211, 45, 10.1002/path.2085 · DOI
  42. Kokkola, 1998, Presence of high-level DNA copy number gains in gastric carcinoma and severely dysplastic adenomas but not in moderately dysplastic adenomas, Cancer Genet Cytogenet, 107, 32, 10.1016/S0165-4608(98)00092-2 · doi:10.1016/s0165-4608(98)00092-2
  43. Koo, 2000, Genetic alterations of gastric cancer: comparative genomic hybridization and fluorescence In situ hybridization studies, Cancer Genet Cytogenet, 117, 97, 10.1016/S0165-4608(99)00152-1 · doi:10.1016/s0165-4608(99)00152-1
  44. Sakakura, 1999, Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization, Genes Chromosomes Cancer, 24, 299, 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U · doi:10.1002/(sici)1098-2264(199904)24:4<299::aid-gcc2>3.0.co;2-u
  45. van Grieken, 2000, Helicobacter pylori-related and -non-related gastric cancers do not differ with respect to chromosomal aberrations, J Pathol, 192, 301, 10.1002/1096-9896(2000)9999:9999<::AID-PATH697>3.0.CO;2-F · doi:10.1002/1096-9896(2000)9999:9999<::aid-path697>3.0.co;2-f
  46. Weiss, 2003, Barrett's adenocarcinomas resemble adenocarcinomas of the gastric cardia in terms of chromosomal copy number changes, but relate to squamous cell carcinomas of the distal oesophagus with respect to the presence of high-level amplifications, J Pathol, 199, 157, 10.1002/path.1260 · doi:10.1002/path.1260
  47. Kimura, 2004, Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression, Mod Pathol, 17, 1328, 10.1038/modpathol.3800180 · DOI
  48. Weiss, 2003, Genomic profiling of gastric cancer predicts lymph node status and survival, Oncogene, 22, 1872, 10.1038/sj.onc.1206350 · DOI
  49. Snijders, 2001, Assembly of microarrays for genome-wide measurement of DNA copy number, Nat Genet, 29, 263, 10.1038/ng754 · DOI · Paper page
  50. Ylstra, 2006, BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH), Nucleic Acids Res, 34, 445, 10.1093/nar/gkj456 · DOI · Paper page
  51. Ott, 2003, Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma, Clin Cancer Res, 9, 2307
  52. Herman, 2003, Gene silencing in cancer in association with promoter hypermethylation, N Engl J Med, 349, 2042, 10.1056/NEJMra023075 · DOI · Paper page
  53. An, 2005, Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma, Clin Cancer Res, 11, 656, 10.1158/1078-0432.656.11.2 · DOI · Paper page
  54. Carvalho, 2003, Concurrent hypermethylation of gene promoters is associated with an MSI-H phenotype and diploidy in gastric carcinomas, Eur J Cancer, 39, 1222, 10.1016/S0959-8049(03)00177-1 · DOI
  55. Stresemann, 2008, Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine, Int J Cancer, 123, 8, 10.1002/ijc.23607 · DOI · Paper page
  56. Fuccio, 2007, Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer, Aliment Pharmacol Ther, 25, 133, 10.1111/j.1365-2036.2006.03183.x · DOI
  57. de Vries, 2007, Review article: Helicobacter pylori eradication for the prevention of gastric cancer, Aliment Pharmacol Ther, 26, 25, 10.1111/j.1365-2036.2007.03475.x · doi:10.1111/j.1365-2036.2007.03475.x
  58. Lai, 2002, Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence, Hepatogastroenterology, 49, 1157
  59. 1998, Japanese classification of gastric carcinoma–2nd English Edn, Gastric Cancer, 1, 10, 10.1007/PL00011681 · DOI · Paper page
  60. Yamashita, 2008, Validation of staging systems for gastric cancer, Gastric Cancer, 11, 111, 10.1007/s10120-008-0466-7 · DOI
  61. Kwee, 2007, Imaging in local staging of gastric cancer: a systematic review, J Clin Oncol, 25, 2107, 10.1200/JCO.2006.09.5224 · doi:10.1200/jco.2006.09.5224
  62. Shinohara, 2005, Clinical value of multidetector row computed tomography in detecting lymph node metastasis of early gastric cancer, Eur J Surg Oncol, 31, 743, 10.1016/j.ejso.2005.03.005 · doi:10.1016/j.ejso.2005.03.005
  63. Noda, 1998, Ignoring small lymph nodes can be a major cause of staging error in gastric cancer, Br J Surg, 85, 831, 10.1046/j.1365-2168.1998.00691.x · doi:10.1046/j.1365-2168.1998.00691.x
  64. Mochiki, 2004, Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer, World J Surg, 28, 247, 10.1007/s00268-003-7191-5 · DOI · Paper page
  65. Blackshaw, 2003, Laparoscopy significantly improves the perceived preoperative stage of gastric cancer, Gastric Cancer, 6, 225, 10.1007/s10120-003-0257-0 · doi:10.1007/s10120-003-0257-0
  66. de Graaf, 2007, The role of staging laparoscopy in oesophagogastric cancers, Eur J Surg Oncol, 33, 988, 10.1016/j.ejso.2007.01.007 · doi:10.1016/j.ejso.2007.01.007
  67. Kayaalp, 2002, Value of computed tomography in addition to ultrasound for preoperative staging of gastric cancer, Eur J Surg Oncol, 28, 540, 10.1053/ejso.2002.1296 · doi:10.1053/ejso.2002.1296
  68. Kim, 2005, Gastric cancer staging at multi-detector row CT gastrography: comparison of transverse and volumetric CT scanning, Radiology, 236, 879, 10.1148/radiol.2363041101 · DOI · Paper page
  69. Sultan, 2008, Endoscopic ultrasonography-detected low-volume ascites as a predictor of inoperability for oesophagogastric cancer, Br J Surg, 95, 1127, 10.1002/bjs.6299 · DOI
  70. Ott, 2008, Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study, Clin Cancer Res, 14, 2012, 10.1158/1078-0432.CCR-07-0934 · DOI
  71. Nakajima, 2002, Gastric cancer treatment guidelines in Japan, Gastric Cancer, 5, 1, 10.1007/s101200200000 · DOI · Paper page
  72. Wang, 2006, Endoscopic mucosal resection for early gastric cancer, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD004276.pub2 · doi:10.1002/14651858.cd004276.pub2
  73. Kim, 2007, EMR for early gastric cancer in Korea: a multicenter retrospective study, Gastrointest Endosc, 66, 693, 10.1016/j.gie.2007.04.013 · doi:10.1016/j.gie.2007.04.013
  74. Fukase, 2008, Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial, Lancet, 372, 392, 10.1016/S0140-6736(08)61159-9 · DOI · Paper page
  75. Gotoda, 2006, Endoscopic submucosal dissection of early gastric cancer, J Gastroenterol, 41, 929, 10.1007/s00535-006-1954-3 · DOI · Paper page
  76. Oda, 2006, A multicenter retrospective study of endoscopic resection for early gastric cancer, Gastric Cancer, 9, 262, 10.1007/s10120-006-0389-0 · doi:10.1007/s10120-006-0389-0
  77. Gotoda, 2000, Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers, Gastric Cancer, 3, 219, 10.1007/PL00011720 · DOI · Paper page
  78. Yasuda, 1999, Rate of detection of lymph node metastasis is correlated with the depth of submucosal invasion in early stage gastric carcinoma, Cancer, 85, 2119, 10.1002/(SICI)1097-0142(19990515)85:10<2119::AID-CNCR4>3.0.CO;2-M · DOI · Paper page
  79. Orsenigo, 2008, Sentinel node mapping during laparoscopic distal gastrectomy for gastric cancer, Surg Endosc, 22, 118, 10.1007/s00464-007-9385-7 · doi:10.1007/s00464-007-9385-7
  80. Park, 2006, Sentinel node biopsy for cT1 and cT2a gastric cancer, Eur J Surg Oncol, 32, 48, 10.1016/j.ejso.2005.09.006 · doi:10.1016/j.ejso.2005.09.006
  81. Saikawa, 2006, Interim results of sentinel node biopsy during laparoscopic gastrectomy: possible role in function-preserving surgery for early cancer, World J Surg, 30, 1962, 10.1007/s00268-006-0142-1 · doi:10.1007/s00268-006-0142-1
  82. Tajima, 2009, Sentinel node mapping guided by indocyanine green fluorescence imaging in gastric cancer, Ann Surg, 249, 58, 10.1097/SLA.0b013e3181927267 · DOI · Paper page
  83. Shehzad, 2007, Current status of minimal access surgery for gastric cancer, Surg Oncol, 16, 85, 10.1016/j.suronc.2007.04.012 · doi:10.1016/j.suronc.2007.04.012
  84. Shiraishi, 2006, Laparoscopic gastrectomy with lymph node dissection for gastric cancer, Gastric Cancer, 9, 167, 10.1007/s10120-006-0380-9 · doi:10.1007/s10120-006-0380-9
  85. Bozzetti, 1999, Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group, Ann Surg, 230, 170, 10.1097/00000658-199908000-00006 · DOI · Paper page
  86. Gouzi, 1989, Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study, Ann Surg, 209, 162, 10.1097/00000658-198902000-00005 · doi:10.1097/00000658-198902000-00005
  87. Kim, 1999, Effect of microscopic resection line disease on gastric cancer survival, J Gastrointest Surg, 3, 24, 10.1016/S1091-255X(99)80004-3 · doi:10.1016/s1091-255x(99)80004-3
  88. Songun, 1996, Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer, Eur J Cancer, 32, 433, 10.1016/0959-8049(95)00591-9 · doi:10.1016/0959-8049(95)00591-9
  89. Cuschieri, 1999, Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group, Br J Cancer, 79, 1522, 10.1038/sj.bjc.6690243 · DOI · Paper page
  90. Dent, 1988, Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma, Br J Surg, 75, 110, 10.1002/bjs.1800750206 · doi:10.1002/bjs.1800750206
  91. Hartgrink, 2004, Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial, J Clin Oncol, 22, 2069, 10.1200/JCO.2004.08.026 · DOI · Paper page
  92. Robertson, 1994, A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer, Ann Surg, 220, 176, 10.1097/00000658-199408000-00009 · doi:10.1097/00000658-199408000-00009
  93. Wu, 2006, Nodal dissection for patients with gastric cancer: a randomised controlled trial, Lancet Oncol, 7, 309, 10.1016/S1470-2045(06)70623-4 · DOI · Paper page
  94. McCulloch, 2004, Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach, Cochrane Database Syst Rev, 4
  95. Sasako, 2008, D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer, N Engl J Med, 359, 453, 10.1056/NEJMoa0707035 · DOI · Paper page
  96. Csendes, 2002, A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma, Surgery, 131, 401, 10.1067/msy.2002.121891 · doi:10.1067/msy.2002.121891
  97. Yu, 2006, Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer, Br J Surg, 93, 559, 10.1002/bjs.5353 · DOI · Paper page
  98. Sano, 2002, Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF, Jpn J Clin Oncol, 32, 363, 10.1093/jjco/hyf085 · doi:10.1093/jjco/hyf085
  99. Kitamura, 1999, No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer, Br J Surg, 86, 119, 10.1046/j.1365-2168.1999.00967.x · doi:10.1046/j.1365-2168.1999.00967.x
  100. Kodera, 1997, Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma, World J Surg, 21, 622, 10.1007/s002689900283 · doi:10.1007/s002689900283
  101. Wang, 2004, A comparative study of pancreatectomy and pancreas-preserving gastrectomy in advanced gastric carcinomas, Hepatogastroenterology, 51, 1229
  102. Kampschoer, 1989, Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients, Br J Surg, 76, 905, 10.1002/bjs.1800760910 · doi:10.1002/bjs.1800760910
  103. Peeters, 2005, Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial, World J Surg, 29, 1576, 10.1007/s00268-005-7907-9 · doi:10.1007/s00268-005-7907-9
  104. Hundahl, 2002, Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment, Ann Surg Oncol, 9, 278, 10.1007/BF02573066 · doi:10.1007/bf02573066
  105. Hundahl, 2007, Improved regional control and survival with low Maruyama Index surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial, Gastric Cancer, 10, 84, 10.1007/s10120-007-0426-7 · doi:10.1007/s10120-007-0426-7
  106. Halm, 2002, Is volume related to outcome in health care? A systematic review and methodologic critique of the literature, Ann Intern Med, 137, 511, 10.7326/0003-4819-137-6-200209170-00012 · DOI · Paper page
  107. Birkmeyer, 2007, Hospital volume and late survival after cancer surgery, Ann Surg, 245, 777, 10.1097/01.sla.0000252402.33814.dd · DOI · Paper page
  108. Damhuis, 2002, Hospital volume and post-operative mortality after resection for gastric cancer, Eur J Surg Oncol, 28, 401, 10.1053/ejso.2001.1246 · DOI
  109. Thompson, 2007, Hospital volume does not influence long-term survival of patients undergoing surgery for oesophageal or gastric cancer, Br J Surg, 94, 578, 10.1002/bjs.5729 · doi:10.1002/bjs.5729
  110. Wenner, 2005, The influence of surgical volume on hospital mortality and 5-year survival for carcinoma of the oesophagus and gastric cardia, Anticancer Res, 25, 419
  111. Xirasagar, 2008, Procedure volume of gastric cancer resections versus 5-year survival, Eur J Surg Oncol, 34, 23, 10.1016/j.ejso.2007.08.002 · doi:10.1016/j.ejso.2007.08.002
  112. Meyer, 2005, The influence of case load and the extent of resection on the quality of treatment outcome in gastric cancer, Eur J Surg Oncol, 31, 595, 10.1016/j.ejso.2005.03.002 · doi:10.1016/j.ejso.2005.03.002
  113. Bachmann, 2002, Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers, Br J Surg, 89, 914, 10.1046/j.1365-2168.2002.02135.x · doi:10.1046/j.1365-2168.2002.02135.x
  114. Birkmeyer, 2003, Surgeon volume and operative mortality in the United States, N Engl J Med, 349, 2117, 10.1056/NEJMsa035205 · DOI · Paper page
  115. Henning, 2000, Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma, Int J Radiat Oncol Biol Phys, 46, 109, 10.1016/S0360-3016(99)00379-X · doi:10.1016/s0360-3016(99)00379-x
  116. Jansen, 2005, Optimal locoregional treatment in gastric cancer, J Clin Oncol, 23, 4509, 10.1200/JCO.2005.21.196 · doi:10.1200/jco.2005.21.196
  117. Smalley, 2002, Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation, Int J Radiat Oncol Biol Phys, 52, 283, 10.1016/S0360-3016(01)02646-3 · doi:10.1016/s0360-3016(01)02646-3
  118. Sindelar, 1993, Randomized trial of intraoperative radiotherapy in carcinoma of the stomach, Am J Surg, 165, 178, 10.1016/S0002-9610(05)80423-4 · doi:10.1016/s0002-9610(05)80423-4
  119. Drognitz, 2008, Long-term results after intraoperative radiation therapy for gastric cancer, Int J Radiat Oncol Biol Phys, 70, 715, 10.1016/j.ijrobp.2007.07.2331 · doi:10.1016/j.ijrobp.2007.07.2331
  120. Hallissey, 1994, The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up, Lancet, 343, 1309, 10.1016/S0140-6736(94)92464-3 · doi:10.1016/s0140-6736(94)92464-3
  121. Bleiberg, 1989, Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC, Eur J Surg Oncol, 15, 535
  122. Skoropad, 2002, Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial, J Surg Oncol, 80, 72, 10.1002/jso.10102 · doi:10.1002/jso.10102
  123. Zhang, 1998, Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)—report on 370 patients, Int J Radiat Oncol Biol Phys, 42, 929, 10.1016/S0360-3016(98)00280-6 · doi:10.1016/s0360-3016(98)00280-6
  124. Fiorica, 2007, The impact of radiotherapy on survival in resectable gastric carcinoma: a meta-analysis of literature data, Cancer Treat Rev, 33, 729, 10.1016/j.ctrv.2007.08.005 · DOI
  125. Moertel, 1984, Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma, J Clin Oncol, 2, 1249, 10.1200/JCO.1984.2.11.1249 · DOI · Paper page
  126. 1982, A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma, Cancer, 49, 1771, 10.1002/1097-0142(19820501)49:9<1771::AID-CNCR2820490907>3.0.CO;2-M · doi:10.1002/1097-0142(19820501)49:9<1771::aid-cncr2820490907>3.0.co;2-m
  127. Klaassen, 1985, Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study, J Clin Oncol, 3, 373, 10.1200/JCO.1985.3.3.373 · doi:10.1200/jco.1985.3.3.373
  128. 1990, The concept of locally advanced gastric cancer. Effect of treatment on outcome, Cancer, 66, 2324, 10.1002/1097-0142(19901201)66:11<2324::AID-CNCR2820661112>3.0.CO;2-C · doi:10.1002/1097-0142(19901201)66:11<2324::aid-cncr2820661112>3.0.co;2-c
  129. Macdonald, 2001, Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med, 345, 725, 10.1056/NEJMoa010187 · DOI · Paper page
  130. Kozak, 2008, The survival impact of the intergroup 0116 trial on patients with gastric cancer, Int J Radiat Oncol Biol Phys, 72, 517, 10.1016/j.ijrobp.2007.12.029 · doi:10.1016/j.ijrobp.2007.12.029
  131. Coburn, 2008, Adjuvant therapy for resected gastric cancer—rapid, yet incomplete adoption following results of intergroup 0116 trial, Int J Radiat Oncol Biol Phys, 70, 1073, 10.1016/j.ijrobp.2007.07.2378 · DOI
  132. Kim, 2005, An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach, Int J Radiat Oncol Biol Phys, 63, 1279, 10.1016/j.ijrobp.2005.05.005 · DOI
  133. Jansen, 2007, Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer, Int J Radiat Oncol Biol Phys, 67, 781, 10.1016/j.ijrobp.2006.09.012 · doi:10.1016/j.ijrobp.2006.09.012
  134. Ringash, 2005, IMRT for adjuvant radiation in gastric cancer: a preferred plan?, Int J Radiat Oncol Biol Phys, 63, 732, 10.1016/j.ijrobp.2005.03.013 · doi:10.1016/j.ijrobp.2005.03.013
  135. Wieland, 2004, IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach, Int J Radiat Oncol Biol Phys, 59, 1236, 10.1016/j.ijrobp.2004.02.051 · doi:10.1016/j.ijrobp.2004.02.051
  136. Kollmannsberger, 2005, Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO, Ann Oncol, 16, 1326, 10.1093/annonc/mdi252 · doi:10.1093/annonc/mdi252
  137. Jansen, 2007, Postoperative chemoradiotherapy in gastric cancer—a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy, Br J Cancer, 97, 712, 10.1038/sj.bjc.6603965 · doi:10.1038/sj.bjc.6603965
  138. Jansen, 2007, A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer, Int J Radiat Oncol Biol Phys, 69, 1424, 10.1016/j.ijrobp.2007.05.004 · DOI
  139. Ajani, 2004, Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma, J Clin Oncol, 22, 2774, 10.1200/JCO.2004.01.015 · doi:10.1200/jco.2004.01.015
  140. Ajani, 2005, Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome, J Clin Oncol, 23, 1237, 10.1200/JCO.2005.01.305 · DOI · Paper page
  141. Ajani, 2006, Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response, J Clin Oncol, 24, 3953, 10.1200/JCO.2006.06.4840 · DOI · Paper page
  142. Allal, 2005, Neoadjuvant radiochemotherapy for locally advanced gastric cancer: long-term results of a phase I trial, Int J Radiat Oncol Biol Phys, 63, 1286, 10.1016/j.ijrobp.2005.05.033 · doi:10.1016/j.ijrobp.2005.05.033
  143. Wydmanski, 2007, The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study, Radiother Oncol, 82, 132, 10.1016/j.radonc.2007.01.009 · doi:10.1016/j.radonc.2007.01.009
  144. Kim, 2008, Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery, Int J Radiat Oncol Biol Phys, 71, 167, 10.1016/j.ijrobp.2007.09.019 · doi:10.1016/j.ijrobp.2007.09.019
  145. Saikawa, 2008, Phase II study of chemoradiotherapy with S-1 and low-dose cisplatin for inoperable advanced gastric cancer, Int J Radiat Oncol Biol Phys, 71, 173, 10.1016/j.ijrobp.2007.09.010 · doi:10.1016/j.ijrobp.2007.09.010
  146. Ajani, 1991, Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy, Cancer, 68, 1501, 10.1002/1097-0142(19911001)68:7<1501::AID-CNCR2820680706>3.0.CO;2-L · doi:10.1002/1097-0142(19911001)68:7<1501::aid-cncr2820680706>3.0.co;2-l
  147. Ott, 2003, Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study, Gastric Cancer, 6, 159, 10.1007/s10120-003-0245-4 · doi:10.1007/s10120-003-0245-4
  148. Hartgrink, 2004, Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial, Eur J Surg Oncol, 30, 643, 10.1016/j.ejso.2004.04.013 · DOI · Paper page
  149. Earle, 1999, Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials, Eur J Cancer, 35, 1059, 10.1016/S0959-8049(99)00076-3 · DOI · Paper page
  150. Gianni, 2001, Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer, Ann Oncol, 12, 1178, 10.1023/A:1011611821258 · DOI
  151. Hermans, 1993, Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials, J Clin Oncol, 11, 1441, 10.1200/JCO.1993.11.8.1441 · doi:10.1200/jco.1993.11.8.1441
  152. Mari, 2000, Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente), Ann Oncol, 11, 837, 10.1023/A:1008377101672 · doi:10.1023/a:1008377101672
  153. Sakuramoto, 2007, Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine, N Engl J Med, 357, 1810, 10.1056/NEJMoa072252 · DOI · Paper page
  154. Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 11, 10.1056/NEJMoa055531 · DOI · Paper page
  155. Boige, 2007, Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial, J Clin Oncol, 25, 4510, 10.1200/jco.2007.25.18_suppl.4510 · doi:10.1200/jco.2007.25.18_suppl.4510
  156. Yu, 1998, Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer, Am Surg, 64, 1104
  157. Yan, 2007, A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer, Ann Surg Oncol, 14, 2702, 10.1245/s10434-007-9487-4 · DOI · Paper page
  158. Glimelius, 1997, Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer, Ann Oncol, 8, 163, 10.1023/A:1008243606668 · DOI · Paper page
  159. Cunningham, 2008, Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 358, 36, 10.1056/NEJMoa073149 · DOI · Paper page
  160. Johnston, 1995, Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors, Cancer Res, 55, 1407
  161. Lenz, 1996, Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival, J Clin Oncol, 14, 176, 10.1200/JCO.1996.14.1.176 · DOI · Paper page
  162. Napieralski, 2005, Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients, Clin Cancer Res, 11, 3025, 10.1158/1078-0432.CCR-04-1605 · DOI
  163. Metzger, 1998, ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy, J Clin Oncol, 16, 309, 10.1200/JCO.1998.16.1.309 · DOI · Paper page
  164. Keam, 2008, Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker, BMC Cancer, 8, 148, 10.1186/1471-2407-8-148 · DOI
  165. Grau, 2008, Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy, J Surg Oncol, 98, 130, 10.1002/jso.21096 · doi:10.1002/jso.21096
  166. Moutinho, 2008, Epidermal growth factor receptor structural alterations in gastric cancer, BMC Cancer, 8, 10, 10.1186/1471-2407-8-10 · doi:10.1186/1471-2407-8-10
  167. Ohtsu, 2008, Chemotherapy for metastatic gastric cancer: past, present, and future, J Gastroenterol, 43, 256, 10.1007/s00535-008-2177-6 · DOI · Paper page
  168. Rivera, 2007, Chemotherapy of advanced gastric cancer, Cancer Treat Rev, 33, 315, 10.1016/j.ctrv.2007.01.004 · DOI
  169. Petrelli, 2004, The debate is over; it's time to move on, J Clin Oncol, 22, 2041, 10.1200/JCO.2004.03.956 · doi:10.1200/jco.2004.03.956
  170. Cunningham, 2007, East meets west in the treatment of gastric cancer, N Engl J Med, 357, 1863, 10.1056/NEJMe078182 · doi:10.1056/nejme078182
  171. Fuchs C, Tepper JE, Niedwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastro-esophageal adenocarcinoma using epirubicin, cisplatin and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): interim toxicity results from Intergroup trial CALGB 80101. 2006 Gastrointestinal Cancer Symposium, San Francisco (CA) 2008; (abstr 61): 115.
  172. 2008, Gastric cancer in Europe, Br J Surg, 95, 406, 10.1002/bjs.6197 · doi:10.1002/bjs.6197

Cited by

See all 875

Metadata

Authors
Hartgrink, H. H., Jansen, E. P., van Grieken, N. C., & van de Velde, C. J.
Venue
The Lancet
Publisher
Elsevier BV
Published
2009-08
Volume
374
Issue
9688
Pages
477-490
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(09)60617-6
OpenAlex
W4211066405
Cited by
875
References
3
FWCI
21.85
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gastric cancer. https://app.cochat.ai/papers/10.1016/s0140-6736(09)60617-6
The paper
Hartgrink, H. H., Jansen, E. P., van Grieken, N. C., & van de Velde, C. J. (2009). Gastric cancer. The Lancet. https://doi.org/10.1016/s0140-6736(09)60617-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.